Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wuxi PharmaTech Obtains Humane Animal Treatment Accreditation For Toxicology Facility In Eastern China

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The leadership of Wuxi PharmaTech, China's dominant contract research organization, said the Shanghai-based outfit is on track to begin offering GLP-compliant drug safety testing services by the second half of the year at its new, leading-edge toxicology center
Advertisement

Related Content

Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit
China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit
WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings
WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings
Advertisement
UsernamePublicRestriction

Register

SC074219

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel